An Integrated Care Pathway for depression in adolescents : protocol for a Type 1 Hybrid Effectiveness-implementation, Non-randomized, Cluster Controlled Trial
© 2024. The Author(s)..
INTRODUCTION: Our group developed an Integrated Care Pathway to facilitate the delivery of evidence-based care for adolescents experiencing depression called CARIBOU-2 (Care for Adolescents who Receive Information 'Bout OUtcomes, 2nd iteration). The core pathway components are assessment, psychoeducation, psychotherapy options, medication options, caregiver support, measurement-based care team reviews and graduation. We aim to test the clinical and implementation effectiveness of the CARIBOU-2 pathway relative to treatment-as-usual (TAU) in community mental health settings.
METHODS AND ANALYSIS: We will use a Type 1 Hybrid Effectiveness-Implementation, Non-randomized Cluster Controlled Trial Design. Primary participants will be adolescents (planned n = 300, aged 13-18 years) with depressive symptoms, presenting to one of six community mental health agencies. All sites will begin in the TAU condition and transition to the CARIBOU-2 intervention after enrolling 25 adolescents. The primary clinical outcome is the rate of change of depressive symptoms from baseline to the 24-week endpoint using the Childhood Depression Rating Scale-Revised (CDRS-R). Generalized mixed effects modelling will be conducted to compare this outcome between intervention types. Our primary hypothesis is that there will be a greater rate of reduction in depressive symptoms in the group receiving the CARIBOU-2 intervention relative to TAU over 24 weeks as per the CDRS-R. Implementation outcomes will also be examined, including clinician fidelity to the pathway and its components, and cost-effectiveness.
ETHICS AND DISSEMINATION: Research ethics board approvals have been obtained. Should our results support our hypotheses, systematic implementation of the CARIBOU-2 intervention in other community mental health agencies would be indicated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC psychiatry - 24(2024), 1 vom: 08. März, Seite 193 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Courtney, Darren B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adolescent |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 19.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12888-023-05297-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36949184X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36949184X | ||
| 003 | DE-627 | ||
| 005 | 20240320234638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240309s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12888-023-05297-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM36949184X | ||
| 035 | |a (NLM)38459453 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Courtney, Darren B |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An Integrated Care Pathway for depression in adolescents |b protocol for a Type 1 Hybrid Effectiveness-implementation, Non-randomized, Cluster Controlled Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a INTRODUCTION: Our group developed an Integrated Care Pathway to facilitate the delivery of evidence-based care for adolescents experiencing depression called CARIBOU-2 (Care for Adolescents who Receive Information 'Bout OUtcomes, 2nd iteration). The core pathway components are assessment, psychoeducation, psychotherapy options, medication options, caregiver support, measurement-based care team reviews and graduation. We aim to test the clinical and implementation effectiveness of the CARIBOU-2 pathway relative to treatment-as-usual (TAU) in community mental health settings | ||
| 520 | |a METHODS AND ANALYSIS: We will use a Type 1 Hybrid Effectiveness-Implementation, Non-randomized Cluster Controlled Trial Design. Primary participants will be adolescents (planned n = 300, aged 13-18 years) with depressive symptoms, presenting to one of six community mental health agencies. All sites will begin in the TAU condition and transition to the CARIBOU-2 intervention after enrolling 25 adolescents. The primary clinical outcome is the rate of change of depressive symptoms from baseline to the 24-week endpoint using the Childhood Depression Rating Scale-Revised (CDRS-R). Generalized mixed effects modelling will be conducted to compare this outcome between intervention types. Our primary hypothesis is that there will be a greater rate of reduction in depressive symptoms in the group receiving the CARIBOU-2 intervention relative to TAU over 24 weeks as per the CDRS-R. Implementation outcomes will also be examined, including clinician fidelity to the pathway and its components, and cost-effectiveness | ||
| 520 | |a ETHICS AND DISSEMINATION: Research ethics board approvals have been obtained. Should our results support our hypotheses, systematic implementation of the CARIBOU-2 intervention in other community mental health agencies would be indicated | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adolescent | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Implementation | |
| 650 | 4 | |a Integrated care pathway | |
| 650 | 4 | |a Measurement-based care | |
| 700 | 1 | |a Barwick, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Amani, Bahar |e verfasserin |4 aut | |
| 700 | 1 | |a Greenblatt, Andrea T |e verfasserin |4 aut | |
| 700 | 1 | |a Aitken, Madison |e verfasserin |4 aut | |
| 700 | 1 | |a Krause, Karolin R |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Brendan F |e verfasserin |4 aut | |
| 700 | 1 | |a Bennett, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Cleverley, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Uliaszek, Amanda A |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Hawke, Lisa D |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Gajaria, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Newton, Amanda S |e verfasserin |4 aut | |
| 700 | 1 | |a Ameis, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Relihan, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Prebeg, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Szatmari, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC psychiatry |d 2001 |g 24(2024), 1 vom: 08. März, Seite 193 |w (DE-627)NLM113122403 |x 1471-244X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:08 |g month:03 |g pages:193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12888-023-05297-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 08 |c 03 |h 193 | ||